Prognostic Value of HHLA2 in Patients with Solid Tumors: A Meta-Analysis

Area of Science:

• Immunology
• Oncology
• Biomarker Research

Background:

• HHLA2 is a B7 family checkpoint molecule with dual co-stimulatory/co-inhibitory functions in cancer immunity.
• Its precise impact on solid cancer patient prognosis remains incompletely understood.

Purpose of the Study:

• To conduct a meta-analysis evaluating the association between HHLA2 expression levels and prognosis in patients with solid cancers.
• To synthesize evidence from multiple studies to determine the clinical significance of HHLA2 in solid tumors.

Main Methods:

• Systematic literature search of PubMed, Embase, Web of Science, Cochrane, and SCOPUS databases.
• Meta-analysis of 18 studies including 2880 patients, assessing overall survival (OS), recurrence-free survival (RFS), and disease-free survival (DFS).
• Hazard ratios (HR) were pooled using R studio software to quantify survival outcomes.

Main Results:

• High HHLA2 expression was significantly associated with worse OS (HR = 1.58).
• Elevated HHLA2 levels correlated with shorter RFS (HR = 1.95) and worse DFS (HR = 1.45).
• These findings were consistent across multiple solid cancer types.

Conclusions:

• High HHLA2 expression serves as a negative prognostic biomarker in solid cancers.
• Targeting HHLA2 may represent a potential therapeutic strategy to improve patient outcomes.
• Further research is warranted to elucidate the mechanisms underlying HHLA2's role in cancer progression.